ArticleCancer management and research2019
An integrated prediction model of recurrence in endometrial endometrioid cancers.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Trial
- scRNA-seq Can Identify Different Cell Populations in Ovarian Cancer Bulk RNA-seq Experiments.International journal of molecular sciences · 2025Article
- Identification of Ovarian High-Grade Serous Carcinoma with Mitochondrial Gene Variation.International journal of molecular sciences · 2025Article
- Identification of HOXB9 to predict prognosis of endometrial cancer based on comprehensive bioinformatics analysis.European journal of medical research · 2023Article
- Integration of Genomic and Clinical Retrospective Data to Predict Endometrioid Endometrial Cancer Recurrence.International journal of molecular sciences · 2022Article
- Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes.International journal of molecular sciences · 2022Article
- Identification of inflammatory-related gene signatures to predict prognosis of endometrial carcinoma.BMC genomic data · 2022Article
- Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer.Cancers · 2022Article
- Machine learning methods to predict presence of residual cancer following hysterectomy.Scientific reports · 2022Article
- Recurrence Features and Factors influencing Post-relapse Survival in Early-stage Endometrial Cancer after Adjuvant Radiotherapy.Journal of Cancer · 2022Article
- Predicting recurrence and metastasis risk of endometrial carcinomaFrontiers in oncology · 2022Article
- Creation and validation of models to predict response to primary treatment in serous ovarian cancer.Scientific reports · 2021Article
- Postoperative Systemic Immune-Inflammation Index (SII): A Superior Prognostic Factor of Endometrial Cancer.Frontiers in surgery · 2021Article
- Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity.Cancers · 2020Article
- Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.